CORE--HYBRIDOMA MONOCLONAL ANTIBODY AND CELL PRODUCTION

核心--杂交瘤单克隆抗体及细胞生产

• 批准号: 6101741
• 负责人: HARRY D BEAR
• 金额: --
• 依托单位: VIRGINIA COMMONWEALTH UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 1999
• 资助国家: 美国
• 起止时间: 1999-02-19 至 1999-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6101741
• 关键词: antibody formation; biomedical facility; cell line; hybridomas; monoclonal antibody; neoplasm /cancer; tissue /cell culture

The Hybridoma and Cell Production Resource was established in 1983 as a shared resource to produce monoclona antibodies, other lymphoid cell products- and to provide immunological reagents, cell lines and cell culture media and additives to Massey Cancer Center investigators. It has been in continuous operation since its inception in 1983 providing services to nearly 30 different laboratories. Dr. Harry D. Bear, Department of Surgery, has been the Director since 1987. The facility, by performing procedures that would be difficult to set up independently, allows research projects to proceed without disruptive and costly delays that would be necessary if monoclonal antibody production were pursued in each individual laboratory of cancer center members. The core personnel also fulfill an educational role in teaching monoclonal antibody and hybridoma technology to investigators, fellows and graduate students. By providing expertise in the production of hybridomas and monoclonal antibodies, the laboratory facilitates the development of new approaches to detection, diagnosis, and treatment of cancer and to basic investigations into the biology of cancer, the host response to cancer and cancer-causing agents. In general, most investigators request development of antibodies against one or two molecular species for identification, detection, blockade and/or purification. In other instances, production of antibody or other cell products from cell lines already available (e.g. from the American Type Culture Collection) is desired. In either situation, the expertise and time required to establish such routine procedures as fusion, cloning. screening and production would be prohibitively expensive and time-consuming for many individual research laboratories within the institution. The facility also provides a frozen cell storage repository for investigators' hybridomas and other cell lines. In response to demand from investigators, this Core will also be providing centralized Mycoplasma testing and "bulk" culture of eukaryotic cell lines. By centralizing these capabilities. this essential biotechnology has been made available to all investigators.

杂交瘤和细胞生产资源成立于1983年，作为一个共享资源，生产单克隆抗体，其他淋巴细胞产品-并提供免疫试剂，细胞系和细胞培养基和添加剂梅西癌症中心的研究人员。自1983年成立以来，它一直在持续运作，为近30个不同的实验室提供服务。哈利·D博士贝尔，外科系，自1987年以来一直担任主任。该设施通过执行难以独立建立的程序，使研究项目能够在没有破坏性和昂贵延迟的情况下进行，如果在癌症中心成员的每个实验室进行单克隆抗体生产，这将是必要的。核心人员还在向研究人员、研究员和研究生教授单克隆抗体和杂交瘤技术方面发挥教育作用。通过提供生产杂交瘤和单克隆抗体的专业知识，该实验室促进了癌症检测，诊断和治疗新方法的开发，以及对癌症生物学，宿主对癌症和致癌物质的反应的基础研究。一般来说，大多数研究者要求开发针对一种或两种分子种类的抗体用于鉴定、检测、阻断和/或纯化。在其他情况下，需要从已经可用的细胞系（例如来自美国典型培养物保藏中心）产生抗体或其他细胞产物。在任何一种情况下，建立诸如融合、克隆等常规程序所需的专业知识和时间。筛选和生产对于机构内的许多单独的研究实验室来说将是极其昂贵和耗时的。该设施还为研究人员的杂交瘤和其他细胞系提供了冷冻细胞储存库。 为了满足研究者的需求，该中心还将提供集中的支原体检测和真核细胞系的“批量”培养。通过集中这些能力。这一基本生物技术已提供给所有研究人员。